This article is more than 5 years old. Information may no longer be current.

ReNeuron, Schepens Eye Research Institute to collaborate on stem cell therapy program

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

GUILDFORD, U.K. — ReNeuron Group and Schepens Eye Research Institute have signed a patent and know-how license agreement concerning ReNeuron's ReN003 stem cell therapy program, which focuses on retinal diseases, according to a press release from ReNeuron.

According to the agreement, ReNeuron will fund the ReN003 program and pay license maintenance fees as well as milestone and royalty payments to Schepens. The ReN003 program is scheduled to enter its clinical phase in about 18 months. Initially the program will target retinitis pigmentosa, but the cells developed may eventually be used in the treatment of other blindness-causing diseases, such as diabetic retinopathy and age-related macular degeneration.

"It is a tremendously exciting time to be working in the field of ocular regeneration. We are therefore delighted to be continuing our collaboration with ReNeuron under this new agreement, bringing us closer to the day when blindness can be treated with stem cells," Michael Young, PhD, associate scientist at Schepens, associate professor of ophthalmology at Harvard Medical School and lead investigator on ReNeuron's collaboration with Schepens, said in the release.